Differential relationships of NMDAR hypofunction and oxidative stress with cognitive decline

[1]  H. Lane,et al.  Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose‐finding, randomized, double‐blind, placebo‐controlled trial for Alzheimer's disease , 2022, Psychiatry and clinical neurosciences.

[2]  H. Lane,et al.  Diagnosing Alzheimer’s Disease Specifically and Sensitively With pLG72 and Cystine/Glutamate Antiporter SLC7A11 AS Blood Biomarkers , 2022, The international journal of neuropsychopharmacology.

[3]  M. Maciejczyk,et al.  Salivary gland dysfunction and salivary redox imbalance in patients with Alzheimer’s disease , 2021, Scientific Reports.

[4]  H. Lane,et al.  Plasma Glutathione Levels Decreased with Cognitive Decline among People with Mild Cognitive Impairment (MCI): A Two-Year Prospective Study , 2021, Antioxidants.

[5]  H. Lane,et al.  Novel Biomarkers of Alzheimer’s Disease: Based Upon N-methyl- D-aspartate Receptor Hypoactivation and Oxidative Stress , 2021, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[6]  M. Rapoport,et al.  Altered central and blood glutathione in Alzheimer’s disease and mild cognitive impairment: a meta-analysis , 2021, Alzheimer's research & therapy.

[7]  M. Fawzy,et al.  Antioxidants-Related Superoxide Dismutase (SOD), Catalase (CAT), Glutathione Peroxidase (GPX), Glutathione-S-Transferase (GST), and Nitric Oxide Synthase (NOS) Gene Variants Analysis in an Obese Population: A Preliminary Case-Control Study , 2021, Antioxidants.

[8]  H. Lane,et al.  Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia , 2021, JAMA network open.

[9]  H. Lane,et al.  Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer’s Disease , 2021, International journal of molecular sciences.

[10]  R. Maccioni,et al.  New Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer's Disease. , 2021, Journal of Alzheimer's disease : JAD.

[11]  G. Small,et al.  Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis , 2021, Journal of internal medicine.

[12]  H. Lane,et al.  Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial , 2021, The international journal of neuropsychopharmacology.

[13]  G. Lizard,et al.  Association Between Oxidative Stress and Altered Cholesterol Metabolism in Alzheimer's Disease Patients. , 2020, Current Alzheimer research.

[14]  P. Sachdev,et al.  Supplementation with γ-glutamylcysteine (γ-GC) lessens oxidative stress, brain inflammation and amyloid pathology and improves spatial memory in a murine model of AD , 2020, Neurochemistry International.

[15]  G. Taglialatela,et al.  Oxidative Damage and Antioxidant Response in Frontal Cortex of Demented and Nondemented Individuals with Alzheimer's Neuropathology , 2020, The Journal of Neuroscience.

[16]  Yuxin Ma,et al.  D-serine Ameliorates Motor and Cognitive Impairments in β-amyloid 1-42 Injected Mice by Inhibiting JNK Signaling Pathway , 2020, Journal of Chemical Neuroanatomy.

[17]  P. Lewczuk,et al.  Clinical significance of fluid biomarkers in Alzheimer’s Disease , 2020, Pharmacological Reports.

[18]  R. Maccioni,et al.  N-Acetyl Cysteine and Catechin-Derived Polyphenols: A Path Toward Multi-Target Compounds Against Alzheimer's Disease. , 2020, Journal of Alzheimer's disease : JAD.

[19]  D. Dwivedi,et al.  Glutathione in Brain: Overview of Its Conformations, Functions, Biochemical Characteristics, Quantitation and Potential Therapeutic Role in Brain Disorders , 2020, Neurochemical Research.

[20]  Michel E. Vandenberghe,et al.  Impairment of Glycolysis-Derived L-Serine Production in Astrocytes Contributes to Cognitive Deficits in Alzheimer's Disease , 2019, SSRN Electronic Journal.

[21]  H. Lane,et al.  Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) , 2020, Neuropsychiatric disease and treatment.

[22]  G. Alves,et al.  Cognitive Assessment Tools for Screening Older Adults With Low Levels of Education: A Critical Review , 2019, Front. Psychiatry.

[23]  D. Dickson,et al.  The neuropathological diagnosis of Alzheimer’s disease , 2019, Molecular Neurodegeneration.

[24]  K. Thomas,et al.  Regulation and Function of Activity-Dependent Homer in Synaptic Plasticity , 2019, Molecular Neuropsychiatry.

[25]  H. Lane,et al.  Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial , 2019, Journal of psychopharmacology.

[26]  H. Lane,et al.  The Role of N-Methyl-D-Aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia , 2019, Front. Pharmacol..

[27]  C. Faustino,et al.  Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease. , 2019, Current Alzheimer research.

[28]  O. Akinloye,et al.  First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid , 2018, Alexandria Journal of Medicine.

[29]  M. Montero‐Odasso,et al.  The Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review , 2018, Journal of Alzheimer's disease : JAD.

[30]  H. Lane,et al.  Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer’s Disease, and Parkinson’s Disease , 2018, Front. Psychiatry.

[31]  G. Perry,et al.  Markers of oxidative damage to lipids, nucleic acids and proteins and antioxidant enzymes activities in Alzheimer's disease brain: A meta‐analysis in human pathological specimens , 2018, Free radical biology & medicine.

[32]  H. Lane,et al.  Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging , 2017, Scientific Reports.

[33]  Louise M. Walsh,et al.  Assessment of the Target Engagement and d-Serine Biomarker Profiles of the d-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756 , 2017, Neurochemical Research.

[34]  N. Herrmann,et al.  Lipid Peroxidation Markers in Coronary Artery Disease Patients with Possible Vascular Mild Cognitive Impairment , 2017, Journal of Alzheimer's disease : JAD.

[35]  J. Bakdash,et al.  Repeated Measures Correlation , 2017, Front. Psychol..

[36]  R. Panizzutti,et al.  The effect of D-serine administration on cognition and mood in older adults , 2016, Oncotarget.

[37]  T. Krahnke,et al.  Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies , 2016, Alzheimer's Research & Therapy.

[38]  D. Bolt,et al.  An approach for estimating item sensitivity to within-person change over time: An illustration using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). , 2016, Psychological assessment.

[39]  Emma Phillips,et al.  Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. , 2016, The Cochrane database of systematic reviews.

[40]  Ashok V. Kumar.  NMDA Receptor Function During Senescence: Implication on Cognitive Performance , 2015, Front. Neurosci..

[41]  J. Laks,et al.  d-serine levels in Alzheimer's disease: implications for novel biomarker development , 2015, Translational Psychiatry.

[42]  Yue-Cune Chang,et al.  Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled Trial , 2014, Biological Psychiatry.

[43]  M. Maes,et al.  The Glutathione System: A New Drug Target in Neuroimmune Disorders , 2014, Molecular Neurobiology.

[44]  I. Hickie,et al.  Glutathione relates to neuropsychological functioning in mild cognitive impairment , 2014, Alzheimer's & Dementia.

[45]  T. Foster,et al.  Linking Redox Regulation of NMDAR Synaptic Function to Cognitive Decline during Aging , 2013, The Journal of Neuroscience.

[46]  Manjari Tripathi,et al.  Brain oxidative stress: detection and mapping of anti-oxidant marker 'Glutathione' in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. , 2012, Biochemical and biophysical research communications.

[47]  K. Hamase,et al.  d-Amino acid oxidase controls motoneuron degeneration through d-serine , 2011, Proceedings of the National Academy of Sciences.

[48]  R. Petersen.  Clinical practice. Mild cognitive impairment. , 2011, The New England journal of medicine.

[49]  Jeremy C Hobart,et al.  The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[50]  P. Lombroso,et al.  The role of STEP in Alzheimer's disease , 2010 .

[51]  S. Scheff,et al.  Oxidative Stress in the Progression of Alzheimer Disease in the Frontal Cortex , 2010, Journal of neuropathology and experimental neurology.

[52]  E. Teng,et al.  Donepezil delays progression to AD in MCI subjects with depressive symptoms , 2009, Neurology.

[53]  Yuko Fujita,et al.  Co-Administration of a D-Amino Acid Oxidase Inhibitor Potentiates the Efficacy of D-Serine in Attenuating Prepulse Inhibition Deficits After Administration of Dizocilpine , 2009, Biological Psychiatry.

[54]  G. Casadesus,et al.  Synaptic dysfunction and oxidative stress in Alzheimer’s disease: Emerging mechanisms , 2006, Journal of cellular and molecular medicine.

[55]  P. Greengard,et al.  Regulation of NMDA receptor trafficking by amyloid-β , 2005, Nature Neuroscience.

[56]  K. Hashimoto,et al.  Possible role of d-serine in the pathophysiology of Alzheimer's disease , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[57]  F. Mora,et al.  Glutamatergic neurotransmission in aging: a critical perspective , 2001, Mechanisms of Ageing and Development.

[58]  M. Freedman,et al.  Increased Peroxidation and Reduced Antioxidant Enzyme Activity in Alzheimer's Disease , 1998, Experimental Neurology.

[59]  Walter Kukull,et al.  Progression to dementia in patients with isolated memory loss , 1997, The Lancet.

[60]  W. D. Ehmann,et al.  Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease , 1995, Neurology.

[61]  K. Jellinger,et al.  Decreased Catalase Activity but Unchanged Superoxide Dismutase Activity in Brains of Patients with Dementia of Alzheimer Type , 1995, Journal of neurochemistry.

[62]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[63]  Y. Miyake,et al.  Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase. , 1992, The Journal of biological chemistry.

[64]  D. Neary,et al.  Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease , 1990, Neuroscience.

[65]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[66]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[67]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[68]  OUP accepted manuscript , 2022, International Journal of Neuropsychopharmacology.

[69]  M. De la Fuente,et al.  Altered Redox State in Whole Blood Cells from Patients with Mild Cognitive Impairment and Alzheimer's Disease. , 2019, Journal of Alzheimer's disease : JAD.

[70]  S. Rai,et al.  Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer’s Disease: Understanding the Therapeutics Strategies , 2014, Molecular Neurobiology.

[71]  J. Cullen,et al.  Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue , 2010, Nature Protocols.

[72]  I. Santana,et al.  Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[73]  E. Díez-Tejedor,et al.  Amino acid concentrations in cerebrospinal fluid and serum in Alzheimer's disease and vascular dementia , 1993, Journal of neural transmission. Parkinson's disease and dementia section.